Neogenomics (NEO) Net Cash Flow (2010 - 2026)

Neogenomics (NEO) has 17 years of Net Cash Flow data on file, last reported at -$604000.0 in Q2 2026.

• Quarterly Net Cash Flow rose 99.68% year-over-year to -$604000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$9.2 million (up 95.39% YoY) and the FY2025 annual result came in at -$207.4 million, down 945.68% from the prior year.
• Net Cash Flow climbed to -$604000.0 in Q2 2026, from -$13.5 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $36.2 million in Q4 2023 to a low of -$191.4 million in Q2 2025.
• A 5-year average of -$9.5 million and a median of -$1.8 million in 2022 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2023 — Net Cash Flow jumped 1330.45% — and 2025, when it sank 926.11%.
• Tracing NEO's Net Cash Flow over 5 years: stood at -$2.9 million in 2022, then jumped by 1330.45% to $36.2 million in 2023, then sank by 86.15% to $5.0 million in 2024, then plunged by 190.26% to -$4.5 million in 2025, then jumped by 86.67% to -$604000.0 in 2026.
• The last three Net Cash Flow figures came in at -$604000.0 (Q2 2026), -$13.5 million (Q1 2026), and -$4.5 million (Q4 2025), per Business Quant data.